MX2017016302A - Agente terapeutico para tratar del sindrome de hunter y metodo de tratamiento. - Google Patents
Agente terapeutico para tratar del sindrome de hunter y metodo de tratamiento.Info
- Publication number
- MX2017016302A MX2017016302A MX2017016302A MX2017016302A MX2017016302A MX 2017016302 A MX2017016302 A MX 2017016302A MX 2017016302 A MX2017016302 A MX 2017016302A MX 2017016302 A MX2017016302 A MX 2017016302A MX 2017016302 A MX2017016302 A MX 2017016302A
- Authority
- MX
- Mexico
- Prior art keywords
- injection
- week
- once
- hunter syndrome
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un agente terapéutico del síndrome de Hunter y, más específicamente, a un agente terapéutico del síndrome de Hunter que puede reducir el número de visitas al hospital de pacientes con síndrome de Hunter a dos veces al mes o menos, al contener una primera composición para inyectarse por vía intravenosa y una segunda composición para inyectarse por vía subcutánea, que presenta un efecto medicinal equivalente o mayor al de una inyección por vía intravenosa convencional una vez a la semana, los pacientes aumentan el cumplimiento de la toma de medicamentos en comparación con los agentes terapéuticos y los métodos de tratamiento convencionales, y permite un mayor bienestar y conveniencia para el paciente. De acuerdo con la presente invención, el método de co-inyección por vía IV/SC muestra un efecto terapéutico equivalente o superior comparado con el de una inyección por vía IV convencional una vez a la semana, mientras que permite a un paciente visitar el hospital con una frecuencia menor que una vez a la semana, como en visitas convencionales, reemplazando el método convencional de inyección por vía IV una vez a la semana, que requiere que el paciente visite el hospital una vez a la semana, por inyecciones por vía SC mediante las cuales un cuidador del paciente puede realizar directamente en casa una cantidad predeterminada de inyecciones por vía intravenosa. Esto va en contra de un concepto convencional de que el efecto terapéutico logrado por una inyección por vía SC no sería superior al efecto terapéutico logrado por una inyección por vía IV. Por lo tanto, la presente invención se refiere a un agente terapéutico y a un método de tratamiento del cual mejora espectacularmente un efecto del tratamiento del síndrome de Hunter con respecto al de una tecnología convencional.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562187867P | 2015-07-02 | 2015-07-02 | |
KR1020150187297A KR20170004814A (ko) | 2015-07-02 | 2015-12-28 | 헌터증후군 치료제 |
PCT/KR2016/007203 WO2017003270A1 (ko) | 2015-07-02 | 2016-07-04 | 헌터증후군 치료제 및 치료방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017016302A true MX2017016302A (es) | 2018-03-23 |
Family
ID=57833331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016302A MX2017016302A (es) | 2015-07-02 | 2016-07-04 | Agente terapeutico para tratar del sindrome de hunter y metodo de tratamiento. |
Country Status (15)
Country | Link |
---|---|
US (2) | US10561713B2 (es) |
EP (1) | EP3318267B1 (es) |
JP (2) | JP6606199B2 (es) |
KR (3) | KR20170004814A (es) |
CN (1) | CN107921091A (es) |
BR (1) | BR112018000051A2 (es) |
CA (1) | CA2990370C (es) |
CL (1) | CL2018000002A1 (es) |
CO (1) | CO2018000196A2 (es) |
EA (1) | EA038110B1 (es) |
ES (1) | ES2866957T3 (es) |
HK (1) | HK1252663A1 (es) |
MX (1) | MX2017016302A (es) |
PE (1) | PE20190351A1 (es) |
PL (1) | PL3318267T3 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111269221B (zh) | 2015-07-02 | 2023-09-26 | 豪夫迈·罗氏有限公司 | 二环内酰胺和其应用方法 |
EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
JP2021500857A (ja) | 2017-10-02 | 2021-01-14 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 酵素補充療法用酵素を含む融合タンパク質 |
WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
KR102671857B1 (ko) | 2018-05-30 | 2024-06-04 | 주식회사 녹십자 | 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물 |
US20210393618A1 (en) * | 2018-10-11 | 2021-12-23 | Indivior Uk Limited | Buprenorphine to treat respiratory depression |
EP3826664A4 (en) * | 2019-02-06 | 2022-10-26 | Sangamo Therapeutics, Inc. | METHOD FOR THE TREATMENT OF TYPE I MUCOPOLYSACCHARIDOSES |
JP2023529686A (ja) | 2020-06-16 | 2023-07-11 | ノベルファーマ株式会社 | グルタル酸尿症治療用組成物及びこの投与方法 |
WO2024144003A1 (ko) * | 2022-12-29 | 2024-07-04 | 주식회사 녹십자 | 뮤코다당질 축적증에서의 안면 이형의 치료용 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012606B2 (en) * | 2009-04-22 | 2015-04-21 | Alteogen, Inc. | In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasng in vivo half-life using same |
US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
CN103179980B (zh) | 2010-06-25 | 2016-09-28 | 夏尔人类遗传性治疗公司 | 艾杜糖醛酸-2-硫酸酯酶的cns递送的方法和组合物 |
UA115648C2 (uk) * | 2010-06-25 | 2017-12-11 | Шае Хюмен Дженетік Терапіс, Інк. | Доставка терапевтичних агентів до цнс |
KR101158673B1 (ko) * | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
BR112014015352A8 (pt) * | 2011-12-23 | 2017-06-13 | Shire Human Genetic Therapies | tratamento de comprometimento cognitivo da síndrome de hunter por distribuição intratecal de iduronato-2-sulfatase |
WO2013148277A1 (en) * | 2012-03-30 | 2013-10-03 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of iduronate- 2-sulfatase |
JP2015013624A (ja) * | 2013-07-08 | 2015-01-22 | 船井電機株式会社 | 手動推進器具 |
-
2015
- 2015-12-28 KR KR1020150187297A patent/KR20170004814A/ko not_active Application Discontinuation
-
2016
- 2016-07-04 BR BR112018000051-5A patent/BR112018000051A2/pt active Search and Examination
- 2016-07-04 KR KR1020187001448A patent/KR20180015256A/ko active Search and Examination
- 2016-07-04 PE PE2017002893A patent/PE20190351A1/es unknown
- 2016-07-04 CN CN201680038666.3A patent/CN107921091A/zh active Pending
- 2016-07-04 PL PL16818303T patent/PL3318267T3/pl unknown
- 2016-07-04 JP JP2017568199A patent/JP6606199B2/ja active Active
- 2016-07-04 MX MX2017016302A patent/MX2017016302A/es unknown
- 2016-07-04 EP EP16818303.6A patent/EP3318267B1/en active Active
- 2016-07-04 CA CA2990370A patent/CA2990370C/en active Active
- 2016-07-04 EA EA201890182A patent/EA038110B1/ru unknown
- 2016-07-04 ES ES16818303T patent/ES2866957T3/es active Active
- 2016-07-04 US US15/738,017 patent/US10561713B2/en active Active
- 2016-07-04 KR KR1020197036839A patent/KR102213055B1/ko active IP Right Grant
-
2018
- 2018-01-02 CL CL2018000002A patent/CL2018000002A1/es unknown
- 2018-01-11 CO CONC2018/0000196A patent/CO2018000196A2/es unknown
- 2018-09-18 HK HK18111970.1A patent/HK1252663A1/zh unknown
-
2019
- 2019-09-05 JP JP2019161855A patent/JP6858231B2/ja active Active
- 2019-11-27 US US16/698,403 patent/US20200093899A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP6858231B2 (ja) | 2021-04-14 |
KR20170004814A (ko) | 2017-01-11 |
KR20190141026A (ko) | 2019-12-20 |
US10561713B2 (en) | 2020-02-18 |
HK1252663A1 (zh) | 2019-05-31 |
US20180303914A1 (en) | 2018-10-25 |
CO2018000196A2 (es) | 2018-03-28 |
PL3318267T3 (pl) | 2021-07-12 |
EP3318267B1 (en) | 2021-02-24 |
PE20190351A1 (es) | 2019-03-07 |
CA2990370A1 (en) | 2017-01-05 |
EA038110B1 (ru) | 2021-07-07 |
JP6606199B2 (ja) | 2019-11-13 |
KR102213055B1 (ko) | 2021-02-08 |
CL2018000002A1 (es) | 2018-06-29 |
JP2020019775A (ja) | 2020-02-06 |
CN107921091A (zh) | 2018-04-17 |
EP3318267A4 (en) | 2019-02-27 |
JP2018519326A (ja) | 2018-07-19 |
ES2866957T3 (es) | 2021-10-20 |
EP3318267A1 (en) | 2018-05-09 |
CA2990370C (en) | 2022-05-17 |
KR20180015256A (ko) | 2018-02-12 |
US20200093899A1 (en) | 2020-03-26 |
EA201890182A1 (ru) | 2018-06-29 |
BR112018000051A2 (pt) | 2018-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017016302A (es) | Agente terapeutico para tratar del sindrome de hunter y metodo de tratamiento. | |
MX366314B (es) | Uso de derivados de insulina por inyecciones con intervalos variables. | |
MX2018005256A (es) | Formulaciones inyectables de toxina botulinica y metodos de uso de las mismas que tienen efecto terapautico o cosmetico de larga duracion. | |
MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
NZ717504A (en) | Methods of treatment of cancer by continuous infusion of coenzyme q10 | |
EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
MX2017008569A (es) | Derivados de glucagon con estabilidad mejorada. | |
MX2019007779A (es) | Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe). | |
PH12020550821A1 (en) | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration | |
MX2018013715A (es) | Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor. | |
EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
MX2016000220A (es) | Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp. | |
MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
RU2014103543A (ru) | Ботулотоксины для применения в способе лечения жировых отложений | |
MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
BR112013010345A2 (pt) | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção | |
MX2018007377A (es) | Composicion de acido hialuronico para inyecciones en el pene. | |
PH12020550066A1 (en) | METHOD FOR TREATING TNFa-RELATED DISEASE | |
MX2021001502A (es) | Tratamiento de verrugas. | |
RU2012123182A (ru) | Способ коррекции психического состояния пациентов и антиоксидантого статуса при органическом расстройстве личности | |
EA201700347A2 (ru) | Средство для эффективного купирования острого и/или хронического болевого синдрома и способ его применения | |
PL414785A1 (pl) | Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną | |
RU2013119140A (ru) | Способ лечения вегетососудистой дистонии у детей и подростков | |
MX2016008214A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida. |